Gabapentin Market Size

  • Report ID: 5130
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Gabapentin Market Size

Gabapentin Market size was over USD 2.1 Billion in 2023 and is poised to cross USD 3.91 Billion by 2036, growing at more than 4.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of gabapentin is evaluated at USD 2.2 Billion.. The growth of the market can be propelled by the increasing number of people suffering from epilepsy. Since, gabapentin belongs to the family of anticonvulsants it is prescribed to control seizures in individuals with epilepsy. As per a report by World Health Organization, globally 5 million people suffer from epilepsy with an LMC diagnosis rate in epilepsy 139 per 100,000 people. 

Another one of the biggest growth drivers boosting the market expansion is the high utilization of gabapentin as a pain management drug, especially during neuropathic pain. This is largely attributable to an increase in chronic pain for illnesses such as diabetic neuropathy, spinal injuries, and shingles, which are difficult to treat with opioids. In 2021, an estimated 20.9% of U.S. adults experienced chronic pain, and 6.9% of adults experienced high-impact chronic pain. 


Gabapentin Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Abhishek Verma


  • Report ID: 5130
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gabapentin is evaluated at USD 2.2 Billion.

The gabapentin market size was over USD 2.1 Billion in 2023 and is poised to cross USD 3.91 Billion by 2036, growing at more than 4.9% CAGR during the forecast period i.e., between 2024-2036. The rising prevalence of neuropathic pain and the increasing availability of generic versions are some of the major factors anticipated to drive the growth of the market.

North America industry is expected to hold 35% of the revenue share by 2036, due to growing prevalence of chronic pain conditions in the region.

Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma., Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Assertio Holdings, Inc., Arbor Pharmaceuticals, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample